With the launch of an adalimumab, Cadila hopes to get a piece of the worldwide biosimilar market for antirheumatic treatments.
Continuing with its string of recent biosimilar launches, Cadila Pharmaceuticals has put an adalimumab biosimilar (Cadalimab) on the Indian market. The drug is available in a prefilled syringe, 40 mg/0.8 ml.
Adalimumab is an antirheumatic drug for the treatment of arthritis, plaque psoriasis, ankylosing spondylitis, Crohn disease, and ulcerative colitis. It references Humira, an AbbVie product, which had net revenues in 2019 of $19.2 billion, $14.9 billion of that in the United States, where the product does not yet face biosimilar competition. By binding with tumor necrosis factor-alpha, the drug helps to prevent inflammation.
A Large Potential Market
There is a potentially large market for Cadalimab. Cadila, based in Ahmedabad, India, noted that roughly 7 million individuals in India have rheumatoid arthritis (RA) and 2.8% of the population has psoriasis. Adalimumab is currently marketed in over 60 countries by multiple companies, according to Transparency Market Research, which noted that the high cost of adalimumab ($2000-$3000 per month) is a barrier to uptake.
In the United States, 6 adalimumab biosimilars have been approved but market entry is not anticipated for any of them before 2023, owing to product exclusivity rights. Mordor Intelligence has forecast an anual growth rate for the adalimumab of 5.1% through 2025, predicting the fastest growth for adalimumab biosimilars in the Asia Pacific region, including India and China, where health care consumers are highly responsive to price changes.
“While these are not life-threatening, psoriasis and RA can be painful to live with. With the launch of Cadalimab, we want to reach these patients with a cost-effective solution and give them a chance at a better life,” Amit Ajmera, company vice president, said in a statement.
Cadila noted this marks the fourth biosimilar launch in the past 2 months. In early August 2020, Cadila launched a teriparatide biosimilar (NuPTH), referencing Lilly’s Forteo, for the treatment of osteoporosis.
In late July, Cadila launched a rituximab (Ritucad), for the treatment of blood cancer, including non-Hodgkin lymphoma, and rheumatoid arthritis, and a bevacizumab (Bevaro), for the treatment of ovarian cancer, glioblastoma multiforme, colorectal cancer, breast cancer, lung cancer, cervical cancer, and kidney cancer. The rituximab biosimilar references Rituxan (Biogen) and the bevacizumab biosimilar, Avastin (Genentech).
Cadila, one of the largest privately held pharmaceutical companies in India, suggested it may have more biosimilar products to launch later this year.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.